

Mattias Mandorfer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8296455/publications.pdf>

Version: 2024-02-01

307
papers

7,271
citations

76326

40
h-index

76900

74
g-index

332
all docs

332
docs citations

332
times ranked

5526
citing authors

#	ARTICLE	IF	CITATIONS
1	Point Shear Wave Elastography by ElastPQ for Fibrosis Screening in Patients with NAFLD: A Prospective, Multicenter Comparison to Vibration-Controlled Elastography. <i>Ultraschall in Der Medizin</i> , 2023, 44, 169-178.	1.5	8
2	Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 978-987.e2.	4.4	12
3	Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2318-2326.e7.	4.4	16
4	Genetic variation in <i>TERT</i> modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. <i>Gut</i> , 2023, 72, 381-391.	12.1	19
5	Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e251-e266.	4.4	25
6	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. <i>Gut</i> , 2022, 71, 415-423.	12.1	28
7	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. <i>Thrombosis and Haemostasis</i> , 2022, 122, 353-362.	3.4	7
8	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1362-1373.e6.	4.4	39
9	Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS. <i>Hepatology Communications</i> , 2022, 6, 621-632.	4.3	2
10	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy â€“ development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	3.7	132
11	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2276-2286.e6.	4.4	42
12	Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. <i>Hepatology</i> , 2022, 75, 610-622.	7.3	18
13	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. <i>Digestive and Liver Disease</i> , 2022, 54, 500-508.	0.9	11
14	Reply. <i>Hepatology</i> , 2022, 75, 764-765.	7.3	0
15	Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis. <i>Platelets</i> , 2022, 33, 879-886.	2.3	5
16	Effect of liver resection-induced increases in hepatic venous pressure gradient on development of postoperative acute kidney injury. <i>BMC Nephrology</i> , 2022, 23, 21.	1.8	3
17	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. <i>Journal of Hepatology</i> , 2022, 76, 1090-1099.	3.7	26
18	Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression. <i>Journal of Personalized Medicine</i> , 2022, 12, 239.	2.5	7

#	ARTICLE	IF	CITATIONS
19	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, 76, 812-821.	3.7	59
20	Baveno VII “Renewing consensus in portal hypertension. <i>Journal of Hepatology</i> , 2022, 76, 959-974.	3.7	890
21	Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5693-5703.	2.3	5
22	The “Viennese epidemic” of acute HCV in the era of direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2022, 29, 385-394.	2.0	10
23	Angiotensin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension. <i>Digestive and Liver Disease</i> , 2022, 54, 1222-1229.	0.9	2
24	Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. <i>Journal of Gastroenterology</i> , 2022, 57, 99-110.	5.1	11
25	Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients. <i>Liver International</i> , 2022, 42, 1297-1307.	3.9	15
26	Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, , .	3.7	0
27	Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide” results of a “real world” study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 144-154.	3.7	46
28	Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD. <i>Journal of Hepatology</i> , 2022, 77, 1005-1013.	3.7	8
29	Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. <i>Hepatology</i> , 2022, 76, 1563-1575.	7.3	45
30	Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. <i>JHEP Reports</i> , 2022, 4, 100513.	4.9	19
31	Fazirsiran for Liver Disease Associated with Alpha ₁ -Antitrypsin Deficiency. <i>New England Journal of Medicine</i> , 2022, 387, 514-524.	27.0	42
32	Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 2569-2580.	4.3	6
33	Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease. <i>Liver International</i> , 2022, 42, 2501-2512.	3.9	16
34	Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. <i>Gut</i> , 2021, 70, 1758-1767.	12.1	51
35	Letter to the Editor: Perioperative Presentation of COVID-19 in a Liver Transplant Recipient. <i>Hepatology</i> , 2021, 73, 868-869.	7.3	1
36	Author response to Letter to the Editor: MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. <i>Liver International</i> , 2021, 41, 221-222.	3.9	0

#	ARTICLE	IF	CITATIONS
37	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , 2021, 73, 1275-1289.	7.3	45
38	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. <i>Journal of Hepatology</i> , 2021, 74, 819-828.	3.7	96
39	Prevalence of anti-Hepatitis E antibodies and impact on disease severity in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2021, 51, 69-79.	3.4	4
40	Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2021, 53, 345-352.	0.9	0
41	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
42	Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. <i>Liver International</i> , 2021, 41, 799-809.	3.9	27
43	Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 421-431.	1.9	4
44	Recent outbreaks of severe hepatitis A virus infections in Vienna. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 335-344.	2.9	11
45	Aro-Aat Reduces Z-AAT Protein in Pizz Patients and Leads to Improvements in Clinically Relevant Liver Biomarkers. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.5	1
46	Populations-basierte Erfassung des Leberphänotyps bei Alpha1-Antitrypsinmangel. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.5	0
47	Author's reply to "Thromboelastometry in patients with advanced chronic liver disease: a complex interplay". <i>Hepatology International</i> , 2021, 15, 522-524.	4.2	0
48	Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. <i>Journal of Personalized Medicine</i> , 2021, 11, 281.	2.5	5
49	Recent advances in the understanding and management of hepatorenal syndrome. <i>Faculty Reviews</i> , 2021, 10, 48.	3.9	5
50	Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure. <i>United European Gastroenterology Journal</i> , 2021, 9, 427-437.	3.8	22
51	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. <i>Hepatology International</i> , 2021, 15, 1160-1173.	4.2	12
52	Prevention of First Decompensation in Advanced Chronic Liver Disease. <i>Clinics in Liver Disease</i> , 2021, 25, 291-310.	2.1	25
53	COVID-19-Related Downscaling of In-Hospital Liver Care Decreased Patient Satisfaction and Increased Liver-Related Mortality. <i>Hepatology Communications</i> , 2021, 5, 1660-1675.	4.3	16
54	Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2021, 15, 922-933.	4.2	14

#	ARTICLE	IF	CITATIONS
55	Outcomes of an HCV elimination program targeting the Viennese MSM population. Wiener Klinische Wochenschrift, 2021, 133, 635-640.	1.9	10
56	Safety of direct oral anticoagulants in patients with advanced liver disease. Liver International, 2021, 41, 2159-2170.	3.9	36
57	Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological response. Liver International, 2021, 41, 2954-2964.	3.9	5
58	This Letter to the Editor is in response to: "Non-hemodynamic effects of beta-blockers in decompensated cirrhosis: In search of an ideal marker"/corresponding author Sanchit SHARMA, M.D. D.M./CGH-01733. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	0
59	The Addition of C-reactive Protein and von Willebrand Factor to Model for End-stage Liver Disease Sodium Improves Prediction of Waitlist Mortality. Hepatology, 2021, 74, 1533-1545.	7.3	17
60	Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients. Liver International, 2021, 41, 2622-2634.	3.9	3
61	COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital. PLoS ONE, 2021, 16, e0256544.	2.5	16
62	VWF-response to NSBB-therapy " worth to re-read!. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	1
63	Direct patient-physician communication via a hepatitis hotline facilitates treatment initiation in patients with poor adherence. Wiener Klinische Wochenschrift, 2021, 133, 452-460.	1.9	7
64	Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. American Journal of Gastroenterology, 2021, 116, 723-732.	0.4	105
65	Einfluss der Augmentationstherapie mit Alpha1-Antitrypsin auf den Leberphänotyp von Individuen mit klassischem Alpha1-Antitrypsin-Mangel (Genotyp Pi*ZZ). Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
66	Covered transjugular intrahepatic portosystemic shunt improves hypersplenism-associated cytopenia in cirrhosis. , 2021, 59, .		0
67	Prediction of hepatocellular carcinoma after sustained virologic response in patients with compensated advanced chronic liver disease. , 2021, 59, .		0
68	Factor VIII/protein C ratio independently predicts liver-related events but does not reflect the hypercoagulable state in patients with advanced-chronic liver disease. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
69	Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
70	Acute haemodynamic response to intravenous propranolol predicts decompensation and mortality in patients with cirrhosis. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
71	Risk evaluation for acute kidney injury and acute-on-chronic liver failure via a blood-based biomarker panel in patients with cirrhosis. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
72	Von Willebrand Factor (VWF) propeptide levels are similarly accurate for assessing portal hypertension as compared to VWF antigen. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0

#	ARTICLE	IF	CITATIONS
73	NSBB-associated VWF-decreases in decompensated cirrhosis indicate a reduced risk of further decompensation, ACLF, and death. , 2021, 59, .		0
74	The link between bacterial translocation, systemic inflammation, and circulatory dysfunction in cirrhosis. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
75	Safety and efficacy of direct oral anticoagulants (DOACs) in Budd-Chiari Syndrome (BCS) - an Austrian multicenter study. , 2021, 59, .		0
76	Antibiotic therapy is associated with worse outcome in patients with hepatocellular carcinoma treated with sorafenib. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
77	Immunoglobulin subtypes and complement levels exhibit distinct dynamics across advanced chronic liver disease stages and predict first or further decompensation. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
78	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. , 2021, 59, .		0
79	Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1485-1493.	3.7	7
80	Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19. Journal of Personalized Medicine, 2021, 11, 1264.	2.5	10
81	Safety of direct oral anticoagulants (DOACs) in patients with advanced liver disease. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
82	Covered TIPS improves renal function in patients with cirrhosis and ascites. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
83	The impact of betablocker treatment on cancer prognosis in patients with advanced hepatocellular carcinoma receiving sorafenib treatment. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
84	Increasing ACE activity in liver disease impacts on fibrinolysis and inflammation - a potential link to COVID-19. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
85	Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
86	Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. United European Gastroenterology Journal, 2021, 9, 1119-1127.	3.8	20
87	Hepatitis C Virus RNA Is Commonly Detectable in Rectal and Nasal Fluids of Patients With High Viremia. Clinical Infectious Diseases, 2020, 71, 1292-1299.	5.8	16
88	Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient. Liver International, 2020, 40, 988-989.	3.9	6
89	Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. Hepatology, 2020, 71, 1023-1036.	7.3	112
90	Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. Liver International, 2020, 40, 194-204.	3.9	45

#	ARTICLE	IF	CITATIONS
91	Portal hypertensive gastropathy is associated with iron deficiency anemia. Wiener Klinische Wochenschrift, 2020, 132, 1-11.	1.9	15
92	Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. Digestive Diseases and Sciences, 2020, 65, 2712-2718.	2.3	4
93	Does the Functional Liver Imaging Score Derived from Gadoteric Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease?. Radiology, 2020, 294, 98-107.	7.3	51
94	The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis. Journal of Gastroenterology, 2020, 55, 533-542.	5.1	18
95	Impact of <i>HSD17B13</i> rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. Liver International, 2020, 40, 393-404.	3.9	20
96	Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers, 2020, 12, 2961.	3.7	8
97	Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension. Hepatology International, 2020, 14, 1083-1092.	4.2	9
98	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	3.7	282
99	Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases. BMC Medicine, 2020, 18, 336.	5.5	5
100	Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. Digestive and Liver Disease, 2020, 52, 1473-1479.	0.9	6
101	MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. Liver International, 2020, 40, 2797-2807.	3.9	27
102	Non-invasive monitoring of liver disease regression in patients with advanced chronic liver disease after sustained virologic response to INF-free therapies. Journal of Hepatology, 2020, 73, S105.	3.7	4
103	Clinical, histological, and biochemical liver phenotype of European adults with heterozygous alpha-1 antitrypsin deficiency (Pi* <i>MZ</i> genotype). Journal of Hepatology, 2020, 73, S547-S548.	3.7	0
104	Impact of genetic variants on liver disease regression in HCV patients with advanced chronic liver disease who achieved SVR to IFN-free therapies. Journal of Hepatology, 2020, 73, S608-S609.	3.7	0
105	Sustained virologic response to direct-acting antivirals does affect the risk of portal vein thrombosis in patients with advanced chronic liver disease. Journal of Hepatology, 2020, 73, S619-S620.	3.7	1
106	Rotational thromboelastometry (rotem)-based assessment of coagulopathy in cirrhotic patients stratified by severity of portal hypertension. Journal of Hepatology, 2020, 73, S697-S698.	3.7	0
107	Differential activation of humoral compensatory mechanisms in distinct stages of portal hypertension. Journal of Hepatology, 2020, 73, S736-S737.	3.7	0
108	Impact of beta blocker therapy on systemic inflammation stratified by hepatic venous pressure gradient response. Journal of Hepatology, 2020, 73, S743-S744.	3.7	0

#	ARTICLE	IF	CITATIONS
109	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. <i>Hepatology International</i> , 2020, 14, 1093-1103.	4.2	12
110	Noninvasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1713-1724.	3.9	14
111	Author response to Letter to the Editor: "ABO, von Willebrand factor/Factor VIII and portal vein thrombosis in decompensated cirrhosis: Too late to unmask the culprit?" <i>Liver International</i> , 2020, 40, 1790-1791.	3.9	3
112	Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*Z vs Pi*ZZ) in Cirrhosis. <i>Liver International</i> , 2020, 40, 1790-1791.	1.3	63
113	Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review. <i>Seminars in Liver Disease</i> , 2020, 40, 240-255.	3.6	46
114	Combination of phosphodiesterase-5 inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. <i>Liver International</i> , 2020, 40, 2228-2241.	3.9	9
115	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1415-1426.	3.9	21
116	HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. <i>Journal of Hepatology</i> , 2020, 73, 113-120.	3.7	58
117	Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. <i>Liver International</i> , 2020, 40, 787-796.	3.9	14
118	Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1619-1627.	2.8	12
119	Novel reliability criteria for controlled attenuation parameter assessments for noninvasive evaluation of hepatic steatosis. <i>United European Gastroenterology Journal</i> , 2020, 8, 321-331.	3.8	30
120	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1140-1150.	3.7	97
121	Where does TIPS fit in the management of patients with cirrhosis?. <i>JHEP Reports</i> , 2020, 2, 100122.	4.9	72
122	Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	51
123	Europäische Studie: Heterozygoter Alpha-1-Antitrypsinmangel (Pi*MZ) führt zu einem intermediären Leber-Phänotyp. , 2020, 58, .		0
124	Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, .	0.5	0
125	Epidemiology of fulminant hepatitis E cases in Vienna - an informative case series. <i>Journal of Hepatology</i> , 2020, 73, S853-S854.	3.7	0
126	Die Augmentation mit Alpha1-Antitrypsin assoziiert bei Patienten mit klassischem Alpha1-Antitrypsin-Mangel (Pi*ZZ-Genotyp) mit besseren Leber-Parametern. , 2020, 58, .		0

#	ARTICLE	IF	CITATIONS
127	Die Therapie mit Alpha-1-Antitrypsin (AAT) assoziiert bei AAT-Mangel mit besseren Leber-bezogenen Parametern. Zeitschrift Fur Gastroenterologie, 2020, 58, .	0.5	0
128	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut, 2019, 68, 1099-1107.	12.1	100
129	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. Liver International, 2019, 39, 127-135.	3.9	39
130	PS-197-Heterozygous alpha1-antitrypsin deficiency (Pi*MZ) is associated with increased liver stiffness and elevated liver enzymes in a multi-center European cohort. Journal of Hepatology, 2019, 70, e122.	3.7	0
131	SAT-114-Impact of farnesoid X receptor polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. Journal of Hepatology, 2019, 70, e680.	3.7	1
132	The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. Liver International, 2019, 39, 2374-2385.	3.9	47
133	Guideline-conform statin use reduces overall mortality in patients with compensated liver disease. Scientific Reports, 2019, 9, 11674.	3.3	6
134	SAT-486-Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e847.	3.7	0
135	Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. United European Gastroenterology Journal, 2019, 7, 850-858.	3.8	18
136	Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. Gastroenterology, 2019, 157, 705-719.e18.	1.3	82
137	PS-021-The development of portosystemic shunts depends on liver dysfunction rather than on PLGF-driven neoangiogenesis. Journal of Hepatology, 2019, 70, e16.	3.7	0
138	PS-067-Increasing incidence of HCV-GT2 as well as reinfections within the ongoing epidemic of acute HCV infections among MSM in Central Europe. Journal of Hepatology, 2019, 70, e40-e41.	3.7	1
139	THU-230-HBV and HDV confection trends in HIV+ patients in Vienna. Journal of Hepatology, 2019, 70, e266.	3.7	0
140	FRI-255-Dynamics of HCV epidemiology among HIV+ patients in Vienna. Journal of Hepatology, 2019, 70, e506-e507.	3.7	1
141	SAT-020-Transjugular intrahepatic portosystemic shunt implantation improves renal function in patients with ascites. Journal of Hepatology, 2019, 70, e633-e634.	3.7	0
142	Editorial: pressure to close the therapeutic window of non-selective beta blockers?. Alimentary Pharmacology and Therapeutics, 2019, 50, 957-958.	3.7	1
143	The impact of hepatic steatosis on portal hypertension. PLoS ONE, 2019, 14, e0224506.	2.5	10
144	PS-186-Functional liver imaging score derived from gadoteric acid-enhanced MRI predicts outcomes in patients with advanced chronic liver disease. Journal of Hepatology, 2019, 70, e115.	3.7	1

#	ARTICLE	IF	CITATIONS
145	Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 395-403.	1.9	13
146	THU-338-Prevalence and dynamics of NAFLD-associated fibrosis among. <i>Journal of Hepatology</i> , 2019, 70, e309.	3.7	0
147	PS-085-The impact of ABO blood group on von Willebrand factor levels and the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, e54.	3.7	0
148	SAT-117-Enhanced liver fibrosis score is an accurate non-invasive predictor of clinically significant and high-risk portal hypertension. <i>Journal of Hepatology</i> , 2019, 70, e681-e682.	3.7	0
149	Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3642-3651.	2.3	8
150	Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment“Is It Worth Measuring?. <i>Current Hepatology Reports</i> , 2019, 18, 174-186.	0.9	38
151	Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2164-2172.	2.8	9
152	Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. <i>AIDS Patient Care and STDs</i> , 2019, 33, 197-206.	2.5	10
153	SAT-077-Intraperitoneal activation of blood coagulation via tissue factor-exposing extracellular vesicles in patients with advanced chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, e661.	3.7	0
154	Inter- and intra-reader agreement for gadoxetic acid“enhanced MRI parameter readings in patients with chronic liver diseases. <i>European Radiology</i> , 2019, 29, 6600-6610.	4.5	19
155	High efficacy of interferon“free therapy for acute hepatitis C in HIV“positive patients. <i>United European Gastroenterology Journal</i> , 2019, 7, 507-516.	3.8	22
156	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. <i>Digestive and Liver Disease</i> , 2019, 51, 1144-1151.	0.9	23
157	Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. <i>United European Gastroenterology Journal</i> , 2019, 7, 651-661.	3.8	7
158	The Renaissance of Cholemic Nephropathy: A Likely Underestimated Cause of Renal Dysfunction in Liver Disease. <i>Hepatology</i> , 2019, 69, 1858-1860.	7.3	10
159	Portal Hypertension after Liver Transplantation“Causes and Management. <i>Current Hepatology Reports</i> , 2019, 18, 59-66.	0.9	3
160	Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. <i>Hepatology Research</i> , 2019, 49, 201-211.	3.4	16
161	Outcomes after placement of a S“ELLA oesophageal stent for refractory variceal bleeding“A national multicentre study. <i>Liver International</i> , 2019, 39, 290-298.	3.9	30
162	Gut-liver axis signaling in portal hypertension. <i>World Journal of Gastroenterology</i> , 2019, 25, 5897-5917.	3.3	67

#	ARTICLE	IF	CITATIONS
163	Intraperitoneal Activation of Blood Coagulation via Tissue Factor Exposing Extracellular Vesicles in Patients with Liver Disease and Ascites. <i>Hamostaseologie</i> , 2019, 39, .	1.9	1
164	Intestinal Biofilms are an endoscopic Feature of Irritable Bowel Syndrome. , 2019, 57, .		0
165	HCV-Scenario over the last decade at the Medical University Vienna: 6023 viremic HCV(+) patients identified with an 'overestimated' number of 3499 patients potentially left to cure. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.5	0
166	The impact of ABO blood type on VWF and factor VIII levels and the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.5	0
167	Impact of farnesoid X receptor (FXR) polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. , 2019, 57, .		0
168	Reliability criteria for controlled attenuation parameter (CAP) for assessing hepatic steatosis using transient elastography. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.5	0
169	Transjugular intrahepatic portosystemic shunt implantation improves renal function in patients with ascites. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.5	0
170	Prevalence of and risk factors for anemia in patients with advanced chronic liver disease. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.5	0
171	The value of different CT-based methods for diagnosing sarcopenia and predicting mortality in patients with cirrhosis. , 2019, 57, .		0
172	Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.5	0
173	Die Substitution mit Alpha1-Antitrypsin ist bei Patienten mit schwerem Alpha1-Antitrypsin-Mangel (Pi*ZZ-Genotyp) mit einer Verbesserung Leber-bezogener Parameter assoziiert. , 2019, 57, .		0
174	Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a doseâ€response study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1162-1169.	3.7	33
175	Heterozygosity for the alphaâ€antitrypsin Z allele in cirrhosis is associated with more advanced disease. <i>Liver Transplantation</i> , 2018, 24, 744-751.	2.4	58
176	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 154, 1694-1705.e4.	1.3	162
177	Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 966-979.	3.7	41
178	Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. <i>Liver International</i> , 2018, 38, 1427-1436.	3.9	31
179	Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 980-988.	3.7	78
180	The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites. <i>Journal of Hepatology</i> , 2018, 68, S730-S731.	3.7	0

#	ARTICLE	IF	CITATIONS
181	Editorial: use of beta-blockers and band ligation in preventing first and recurrent variceal bleeding – cereal life vs evidence-based decisions. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1224-1225.	3.7	1
182	Role of alpha-1 antitrypsin genotypes in the progression of adult liver disease. <i>Journal of Hepatology</i> , 2018, 68, S618.	3.7	1
183	Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response. <i>Gastroenterology</i> , 2018, 154, 1550-1551.	1.3	9
184	ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. <i>Liver International</i> , 2018, 38, 1036-1044.	3.9	28
185	Role of diuretics in the harmful effects of beta blockers in patients with ascites. Authors' reply. <i>Digestive and Liver Disease</i> , 2018, 50, 102-103.	0.9	1
186	Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 86-94.	3.7	36
187	Transferrin as a predictor of survival in cirrhosis. <i>Liver Transplantation</i> , 2018, 24, 343-351.	2.4	27
188	Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfecting patients. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 105-114.	1.9	14
189	Editorial: surviving your genes – the role of <i>PNPLA3</i> variation in end-stage liver disease. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 775-776.	3.7	0
190	Small Esophageal Varices in Patients with Cirrhosis – Should We Treat Them?. <i>Current Hepatology Reports</i> , 2018, 17, 301-315.	0.9	17
191	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2578-2586.	1.5	11
192	Pharmacological decrease of liver stiffness is pressure-related and predicts long-term clinical outcome. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G484-G494.	3.4	29
193	Outcome after the use of SX-ELLA Danis bleeding stents for refractory variceal bleeding- a Vienna Multicenter Experience. <i>Journal of Hepatology</i> , 2018, 68, S729-S730.	3.7	0
194	Liver fibrosis and metabolic alterations in adults with homozygous alpha1-antitrypsin deficiency (PiZZ). <i>Journal of Hepatology</i> , 2018, 68, S707-S708.	3.7	1
195	Resolution of clinically significant portal hypertension after sustained virologic response to interferon-free regimens prevents hepatic decompensation. <i>Journal of Hepatology</i> , 2018, 68, S532.	3.7	2
196	Alpha1-antitrypsin augmentation therapy is associated with an improvement in liver-related parameters in patients with severe alpha1-antitrypsin-deficiency. <i>Journal of Hepatology</i> , 2018, 68, S621-S622.	3.7	0
197	The impact of hepatic steatosis on portal hypertension. <i>Journal of Hepatology</i> , 2018, 68, S707.	3.7	0
198	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. <i>Journal of Hepatology</i> , 2018, 68, S707-S708.	3.7	0

#	ARTICLE	IF	CITATIONS
199	Impact of patatin-like phospholipase domain containing <i>3 rs738409</i> G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 451-459.	3.7	26
200	Prevalence and resistance rates of infections with enterococci in patients with cirrhosis. <i>Journal of Hepatology</i> , 2018, 68, S694.	3.7	0
201	Effectiveness of early TIPS implantation versus late TIPS versus standard endoscopic treatment for acute variceal bleeding in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2018, 68, S694-S695.	3.7	5
202	Effect of vardenafil on portal hemodynamics in patients with mild and moderate liver dysfunction: a randomized, placebo-controlled trial. <i>Journal of Hepatology</i> , 2018, 68, S717.	3.7	1
203	Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoteric Acid-Enhanced MRI. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-9.	0.8	7
204	Liver disease in adults with antitrypsin deficiency. <i>United European Gastroenterology Journal</i> , 2018, 6, 710-718.	3.8	23
205	High efficacy of IFN-free DAA therapy for acute HCV infection in HIV patients. <i>Journal of Hepatology</i> , 2018, 68, S273.	3.7	1
206	Impact of SVR to IFN-free DAA therapy on steatosis in HIV/HCV coinfecting patients. <i>Journal of Hepatology</i> , 2018, 68, S548.	3.7	1
207	Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding – A two decades experience. <i>PLoS ONE</i> , 2018, 13, e0189414.	2.5	20
208	Editorial: von Willebrand factor and CRP levels may predict survival in liver cirrhosis – Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1537-1538.	3.7	1
209	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 446-455.	1.9	41
210	Controlled attenuation parameter (CAP®) does not predict hepatic decompensation in patients with compensated advanced chronic liver disease. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, .	0.5	0
211	The impact of hepatic steatosis on portal hypertension. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, .	0.5	0
212	Prevalence and Resistance Rates of Infections with Enterococci in Patients with Cirrhosis. , 2018, 56, .		0
213	Limited diagnostic performance of controlled attenuation parameter for assessing hepatic steatosis in patients with advanced chronic liver disease and portal hypertension. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, .	0.5	0
214	Transjugular liver biopsy performed by Hepatologists trained in hepatic venous pressure gradient measurements is safe and provides important diagnostic and prognostic information. , 2018, 56, .		0
215	Gadoxetic acid enhanced MRI distinguishes advanced chronic liver disease patients with improving liver function after sustained virologic response and patients with persistent liver damage. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, .	0.5	0
216	High prevalence of dyslipidemia but insufficient statin use in patients with non-cirrhotic and cirrhotic liver disease. , 2018, 56, .		0

#	ARTICLE	IF	CITATIONS
217	The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites. , 2018, 56, .		0
218	Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 184-190.	2.8	17
219	Prevention of progression from small to large varices: are we there yet? An updated meta-analysis. Gut, 2017, 66, 1347-1349.	12.1	22
220	Letter: sustained virological response and liver healing " authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1173-1174.	3.7	2
221	Interferon-free regimens improve portal hypertension and histological necroinflammation in <scp>HIV</scp>/<scp>HCV</scp> patients with advanced liver disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 139-149.	3.7	83
222	Von Willebrand factor antigen predicts portal hypertensive bleeding, infections, and survival, independently of portal hypertension severity. Journal of Hepatology, 2017, 66, S373-S374.	3.7	0
223	Reply to: "Beta adrenergic blockade and advanced cirrhosis: Does it really improve survival in patients with acute-on-chronic liver failure?" Journal of Hepatology, 2017, 67, 880-881.	3.7	0
224	Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. Scandinavian Journal of Gastroenterology, 2017, 52, 1-8.	1.5	13
225	Editorial: direct acting antivirals - not the be-all and end-all in HIV/HCV co-infection. Authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 570-571.	3.7	0
226	Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth-III). Wiener Klinische Wochenschrift, 2017, 129, 135-158.	1.9	111
227	Bacterial infections in cirrhosis " a retrospective analysis updating on microbiology and resistance rates. Journal of Hepatology, 2017, 66, S577.	3.7	0
228	The novel point shear-wave elastography method ElastPQ Â® is accurate for non-invasive evaluation of liver fibrosis and portal hypertension. Journal of Hepatology, 2017, 66, S674.	3.7	2
229	Heterozygous carriage of the alpha1-antitrypsin Z variant rs28929474 predisposes to the development of cirrhosis in the presence of alcohol misuse and non-alcohol-related fatty liver disease. Journal of Hepatology, 2017, 66, S177.	3.7	6
230	Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. Digestive and Liver Disease, 2017, 49, 1360-1367.	0.9	28
231	Reply to: "Non selective beta blockers in cirrhosis" Journal of Hepatology, 2017, 67, 1343-1344.	3.7	0
232	Effects of Portal Hypertension on Gadoteric Acid-Enhanced Liver Magnetic Resonance. Investigative Radiology, 2017, 52, 462-469.	6.2	14
233	Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. Wiener Klinische Wochenschrift, 2017, 129, 517-526.	1.9	9
234	Multi-center study of liver disease in alpha1-antitrypsin deficiency: non-invasive evaluation of liver fibrosis in homozygous PiZZ patients. Journal of Hepatology, 2017, 66, S176-S177.	3.7	1

#	ARTICLE	IF	CITATIONS
235	Beta adrenergic blockade and decompensated cirrhosis. <i>Journal of Hepatology</i> , 2017, 66, 849-859.	3.7	127
236	Beta blockers and cirrhosis, 2016. <i>Digestive and Liver Disease</i> , 2017, 49, 3-10.	0.9	64
237	Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 8-15.	1.9	44
238	HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. <i>Journal of Hepatology</i> , 2017, 66, 282-287.	3.7	154
239	EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs. <i>Disease Markers</i> , 2017, 2017, 1-9.	1.3	37
240	Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. <i>Aids</i> , 2016, 30, 1039-1047.	2.2	42
241	The trigger matters – outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. <i>Liver International</i> , 2016, 36, 1649-1656.	3.9	10
242	Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease. <i>Medicine (United States)</i> , 2016, 95, e4061.	1.0	18
243	Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. <i>Journal of Hepatology</i> , 2016, 65, 692-699.	3.7	245
244	HCV Reinfection Incidence and Outcomes among HIV Infected MSM in Western Europe. <i>Journal of Hepatology</i> , 2016, 64, S138-S139.	3.7	5
245	Letter: can persisting liver stiffness indicate increased risk for HCC, after successful anti-HCV therapy? - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 544-545.	3.7	1
246	Nonselective beta blockers in patients with ascites: implications of a nationwide study. <i>Liver International</i> , 2016, 36, 1255-1257.	3.9	2
247	Liver Stiffness Assessed by Transient Elastography can not Predict the Hemodynamic Response to Non-Selective Betablockers. <i>Journal of Hepatology</i> , 2016, 64, S287-S288.	3.7	0
248	Interferon-Free Daa Regimens Decrease Portal Pressure and Halt Histological Necroinflammation in HIV/HCV coinfecting Patients. <i>Journal of Hepatology</i> , 2016, 64, S623.	3.7	0
249	Exclusion of Varices Via Transient Elastography Combined with Platelet Count According to the Baveno VI Guidelines can Only be Made for Large not Small Varices. <i>Journal of Hepatology</i> , 2016, 64, S283.	3.7	4
250	Interferon-Free Treatment with Sofosbuvir Plus Daclatasvir Achieves Sustained Virologic Response in 100% of Difficult-To-Treat HIV/HCV-Coinfected Patients and Decreases Liver Stiffness. <i>Journal of Hepatology</i> , 2016, 64, S796-S797.	3.7	0
251	The Evolution of Portal Pressure after Viral Suppression with Interferon-Free Therapies and its Correlation with the Change in Liver Stiffness. <i>Journal of Hepatology</i> , 2016, 64, S138.	3.7	1
252	Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 414-420.	1.9	1

#	ARTICLE	IF	CITATIONS
253	Advances in the management of HIV/HCV coinfection. <i>Hepatology International</i> , 2016, 10, 424-435.	4.2	47
254	Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP). <i>Journal of Hepatology</i> , 2016, 64, 1452-1454.	3.7	13
255	Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients. <i>PLoS ONE</i> , 2016, 11, e0145319.	2.5	5
256	Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria. <i>PLoS ONE</i> , 2016, 11, e0152910.	2.5	30
257	P0884 : Interferon and ribavirin-free therapy with sofosbuvir and daclatasvir in a real-life cohort of difficult-to-treat HIV/HCV-coinfected patients with and without portal hypertension. <i>Journal of Hepatology</i> , 2015, 62, S673-S674.	3.7	0
258	P0191 : IFN-free regimens overcome the negative effect of portal hypertension on virologic response and viral kinetics in patients with cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, S376.	3.7	0
259	P0385 : Prognostic impact of the Baveno IV staging system of portal hypertension in patients with cirrhosis and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2015, 62, S457.	3.7	0
260	Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 707-718.	3.7	44
261	Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1657-1665.	2.8	37
262	Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient. <i>Liver International</i> , 2015, 35, 2115-2120.	3.9	54
263	Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. <i>PLoS ONE</i> , 2015, 10, e0125080.	2.5	12
264	Performance of 2-D Shear Wave Elastography in Liver Fibrosis Assessment Compared with Serologic Tests and Transient Elastography in Clinical Routine. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 2340-2349.	1.5	23
265	Response-Guided Boceprevir-based Triple Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study. <i>Journal of Infectious Diseases</i> , 2015, 211, 729-735.	4.0	10
266	Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. <i>Liver International</i> , 2015, 35, 2121-2128.	3.9	72
267	O094 : The presence of echocardiographic abnormalities increases mortality in patients with spontaneous bacterial peritonitis. <i>Journal of Hepatology</i> , 2015, 62, S241-S242.	3.7	1
268	P0208 : Hemodynamic response to non-selective beta-blockers is not influenced by the presence of metabolic syndrome. <i>Journal of Hepatology</i> , 2015, 62, S383-S384.	3.7	0
269	P0212 : Identifying the trigger matters " outcome of severe acute kidney injury in patients with cirrhosis and ascites. <i>Journal of Hepatology</i> , 2015, 62, S385.	3.7	1
270	P0218 : Factors associated with hemodynamic response to propranolol and carvedilol in cirrhotic patients. <i>Journal of Hepatology</i> , 2015, 62, S388.	3.7	0

#	ARTICLE	IF	CITATIONS
271	P0717 : The presence of a PNPLA3 (rs738409) single nucleotide polymorphism (SNP) is not associated with increased risk for fibrosis, portal hypertension, and hepatic steatosis in HIV/HCV-coinfected patients. <i>Journal of Hepatology</i> , 2015, 62, S593.	3.7	0
272	P0740 : Usefulness of interferon LAMBDA4, HLA class II-polymorphism and killer-immunglobulin -like receptor-2DL3:C1/C1 to predict spontaneous clearance of acute hepatitis C virus infection. <i>Journal of Hepatology</i> , 2015, 62, S602-S603.	3.7	0
273	P0783 : Viral kinetics during interferon-free sofosbuvir containing treatment regimens in a real-life cohort of chronic hepatitis C patients with advanced liver disease. <i>Journal of Hepatology</i> , 2015, 62, S625.	3.7	1
274	P0871 : Real life experience with interferon/ribavirin-free antiviral treatment in renal transplant recipients and endstage renal disease-patients on dialysis infected with hepatitis C virus. <i>Journal of Hepatology</i> , 2015, 62, S667.	3.7	3
275	HCV targeting of patients with cirrhosis. <i>Journal of Hepatology</i> , 2015, 63, 1015-1022.	3.7	54
276	OO19 : The value of different non-invasive tests for predicting the presence of clinically significant portal hypertension and esophageal varices in cirrhotic patients. <i>Journal of Hepatology</i> , 2015, 62, S200.	3.7	0
277	New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. <i>Liver International</i> , 2015, 35, 381-390.	3.9	111
278	Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. <i>Liver International</i> , 2015, 35, 876-885.	3.9	32
279	Circulating MiRNA-122 Levels Are Associated with Hepatic Necroinflammation and Portal Hypertension in HIV/HCV Coinfection. <i>PLoS ONE</i> , 2015, 10, e0116768.	2.5	21
280	Association of CMV-Specific T Cell-Mediated Immunity with CMV DNAemia and Development of CMV Disease in HIV-1-infected Individuals. <i>PLoS ONE</i> , 2015, 10, e0137096.	2.5	5
281	The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. <i>PLoS ONE</i> , 2015, 10, e0143429.	2.5	23
282	Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy. <i>Antiviral Therapy</i> , 2014, 19, 407-414.	1.0	5
283	IFNL4 ss469415590 Variant Shows Similar Performance to rs12979860 as Predictor of Response to Treatment against Hepatitis C Virus Genotype 1 or 4 in Caucasians. <i>PLoS ONE</i> , 2014, 9, e95515.	2.5	24
284	PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension. <i>PLoS ONE</i> , 2014, 9, e108544.	2.5	29
285	The association of smoking with IGRA and TST results in HIV-1-infected subjects. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 709-716.	1.2	5
286	Revisiting predictors of virologic response to PEGIFN+RBV therapy in HIV/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels. <i>Journal of Viral Hepatitis</i> , 2014, 21, 33-41.	2.0	12
287	Nonselective β^2 Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis. <i>Gastroenterology</i> , 2014, 146, 1680-1690.e1.	1.3	336
288	P781 SPONTANEOUS CLEARANCE RATES INCREASE WITH HCV REINFECTION EPISODE IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN (MSM) INDEPENDENT OF HCV SUBTYPE. <i>Journal of Hepatology</i> , 2014, 60, S331.	3.7	2

#	ARTICLE	IF	CITATIONS
289	P954 PROTON PUMP INHIBITOR TREATMENT IS NEITHER ASSOCIATED WITH SPONTANEOUS BACTERIAL PERITONITIS DEVELOPMENT NOR WITH MORTALITY IN CIRRHOTIC PATIENTS WITH ASCITES. <i>Journal of Hepatology</i> , 2014, 60, S393.	3.7	0
290	Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. <i>Liver International</i> , 2014, 34, 69-77.	3.9	35
291	P1038 NEW QUALITY CRITERIA FOR TRANSIENT ELASTOGRAPHY CAN INCREASE THE PROPORTION OF VALID MEASUREMENTS WITH HIGH ACCURACY FOR DETECTION OF LIVER CIRRHOSIS AND PORTAL HYPERTENSION. <i>Journal of Hepatology</i> , 2014, 60, S421.	3.7	2
292	Reversion and Conversion of Interferon- β Release Assay Results in HIV-1 Infected Individuals. <i>Journal of Infectious Diseases</i> , 2014, 209, 729-733.	4.0	25
293	Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV/HBV co-infected patients. <i>Journal of Viral Hepatitis</i> , 2014, 21, 508-516.	2.0	14
294	Reply. <i>Gastroenterology</i> , 2014, 147, 942.	1.3	1
295	Therapeutic Potential of and Treatment with Boceprevir/Telaprevir-Based Triple-Therapy in HIV/Chronic Hepatitis C Co-Infected Patients in a Real-World Setting. <i>AIDS Patient Care and STDs</i> , 2014, 28, 221-227.	2.5	11
296	P504 HEMODYNAMIC RESPONSE TO NON-SELECTIVE BETA BLOCKERS DESPITE LACK OF EFFECTS ON HEART RATE AND SYSTEMIC BLOOD PRESSURE. <i>Journal of Hepatology</i> , 2014, 60, S237.	3.7	0
297	O76 THE OCCURRENCE OF SPONTANEOUS BACTERIAL PERITONITIS CLOSES THE THERAPEUTIC WINDOW OF OPPORTUNITY FOR NON-SELECTIVE BETA BLOCKER TREATMENT IN CIRRHOTIC PATIENTS WITH ASCITES. <i>Journal of Hepatology</i> , 2014, 60, S31-S32.	3.7	0
298	Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites. <i>PLoS ONE</i> , 2014, 9, e110503.	2.5	55
299	84 IMPROVEMENT OF INTESTINAL PERMEABILITY AND REDUCING BACTERIAL TRANSLOCATION BY BETABLOCKER TREATMENT IS ASSOCIATED WITH A LOWER RISK OF VARICEAL BLEEDING. <i>Journal of Hepatology</i> , 2013, 58, S37.	3.7	0
300	Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 911-921.	3.7	269
301	354 PREVALENCE OF AND RISK FACTORS FOR COMBINED cART ASSOCIATED DRUG-INDUCED LIVER INJURY IN HIV/HBV COINFECTED, HIV/HCV COINFECTED, AND HIV MONOINFECTED PATIENTS. <i>Journal of Hepatology</i> , 2013, 58, S147.	3.7	0
302	860 REVISITING PREDICTORS OF VIROLOGIC RESPONSE TO PEGIFN+RBV THERAPY IN HIV/HCV COINFECTED PATIENTS: THE ROLE OF METABOLIC FACTORS AND ELEVATED GGT LEVELS. <i>Journal of Hepatology</i> , 2013, 58, S352-S353.	3.7	0
303	475 THE INFLUENCE OF PORTAL PRESSURE ON THE DISCORDANCE OF ABSOLUTE CD4+ COUNT AND CD4+ PERCENTAGE IN HIV/HCV COINFECTED PATIENTS. <i>Journal of Hepatology</i> , 2013, 58, S194-S195.	3.7	0
304	The Influence of Portal Pressure on the Discordance Between Absolute CD4+ Cell Count and CD4+ Cell Percentage in HIV/Hepatitis C Virus Coinfected Patients. <i>Clinical Infectious Diseases</i> , 2013, 56, 904-905.	5.8	9
305	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. <i>Aids</i> , 2013, 27, 2707-2714.	2.2	15
306	Low vitamin D levels are associated with impaired virologic response to PEGIFN+RBV therapy in HIV hepatitis C virus coinfected patients. <i>Aids</i> , 2013, 27, 227-232.	2.2	39

#	ARTICLE	IF	CITATIONS
307	907 LOW VITAMIN D SERUM LEVELS ARE ASSOCIATED WITH LIVER FIBROSIS AND IMPAIRED VIROLOGIC RESPONSE TO ANTIVIRAL THERAPY WITH PEGIFN+RBV IN HIV/HCV COINFECTED PATIENTS. Journal of Hepatology, 2012, 56, S353.	3.7	0